Am J Epidemiol 2003; 158:915-920.
Copyright © 2003 by Johns
Hopkins Bloomberg School of Public Health
SPECIAL ARTICLE |
Evaluating Medication Effects Outside of Clinical Trials: New-User Designs
1 Division of Pharmacoepidemiology, Department of Preventive Medicine, Vanderbilt University School of Medicine, Nashville, TN.
2 Geriatric Research, Education and Clinical Center, Nashville Veteran’s Administration Medical Center (WAR), Nashville, TN.
Recent clinical trials demonstrating that hormone replacement therapy (HRT) does not prevent coronary heart disease in women have again raised doubts concerning observational studies. Although much of the explanation probably lies in what might be called the "healthy HRT user" effect, another contributing factor may be that most observational studies included many prevalent users: women taking HRT for some time before study follow-up began. This practice can cause two types of bias, both of which plausibly may have contributed to the discrepancy between observational and randomized studies. First, prevalent users are "survivors" of the early period of pharmacotherapy, which can introduce substantial bias if risk varies with time, just as in studies of operative procedures that enroll patients after they have survived surgery. This article provides several examples of medications for which the hazard function varies with time and thus would be subject to prevalent user bias. Second, covariates for drug users at study entry often are plausibly affected by the drug itself. Investigators often do not adjust for these factors on the causal pathway, which may introduce confounding. A new-user design eliminates these biases by restricting the analysis to persons under observation at the start of the current course of treatment. This article thus argues that such designs should be used more frequently in pharmacoepidemiology.
bias (epidemiology); confounding factors (epidemiology); epidemiologic research design; hormone replacement therapy; pharmacoepidemiology; research design
Abbreviations: Abbreviation: HRT, hormone replacement therapy.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H. T. Sorensen, S. Christensen, F. Mehnert, L. Pedersen, R. D Chapurlat, S. R Cummings, and J. A Baron Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study BMJ, April 12, 2008; 336(7648): 813 - 816. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Hylek and J. W. Magnani Methodological considerations for interpretation of rates of major haemorrhage in studies of anticoagulant therapy for atrial fibrillation Europace, January 1, 2008; 10(1): 3 - 5. [Full Text] [PDF]
|
|
|
|
 |
|
 A. G. Winterstein, T. Gerhard, J. Shuster, M. Johnson, J. M. Zito, and A. Saidi Cardiac Safety of Central Nervous System Stimulants in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder Pediatrics, December 1, 2007; 120(6): e1494 - e1501. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Gill and D. P. Seitz Association of Antipsychotics With Mortality Among Elderly Patients With Dementia Am J Geriatr Psychiatry, November 1, 2007; 15(11): 983 - 984. [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Gill, S. E. Bronskill, S.-L. T. Normand, G. M. Anderson, K. Sykora, K. Lam, C. M. Bell, P. E. Lee, H. D. Fischer, N. Herrmann, et al. Antipsychotic Drug Use and Mortality in Older Adults with Dementia Ann Intern Med, June 5, 2007; 146(11): 775 - 786. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Hylek, C. Evans-Molina, C. Shea, L. E. Henault, and S. Regan Major Hemorrhage and Tolerability of Warfarin in the First Year of Therapy Among Elderly Patients With Atrial Fibrillation Circulation, May 29, 2007; 115(21): 2689 - 2696. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Huerta, S. Johansson, M.-A. Wallander, and L. A. Garcia Rodriguez Risk Factors and Short-term Mortality of Venous Thromboembolism Diagnosed in the Primary Care Setting in the United Kingdom Arch Intern Med, May 14, 2007; 167(9): 935 - 943. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N.-K. Choi, S. Hahn, and B.-J. Park Increase in Mortality Rate Following Coprescription of Cisapride and Contraindicated Drugs Ann. Pharmacother., April 1, 2007; 41(4): 667 - 673. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Schneeweiss, S. Setoguchi, A. Brookhart, C. Dormuth, and P. S. Wang Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients Can. Med. Assoc. J., February 27, 2007; 176(5): 627 - 632. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Setoguchi, R. J. Glynn, J. Avorn, H. Mogun, and S. Schneeweiss Statins and the Risk of Lung, Breast, and Colorectal Cancer in the Elderly Circulation, January 2, 2007; 115(1): 27 - 33. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R Majumdar, F. A McAlister, D. T Eurich, R. S Padwal, and T. J Marrie Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study BMJ, November 11, 2006; 333(7576): 999 - 999. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Go, W. Y. Lee, J. Yang, J. C. Lo, and J. H. Gurwitz Statin therapy and risks for death and hospitalization in chronic heart failure. JAMA, November 1, 2006; 296(17): 2105 - 2111. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Schneider, L. E. Levesque, B. Zhang, T. Hutchinson, and J. M. Brophy Association of Selective and Conventional Nonsteroidal Antiinflammatory Drugs with Acute Renal Failure: A Population-based, Nested Case-Control Analysis Am. J. Epidemiol., November 1, 2006; 164(9): 881 - 889. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. de Vries, C. de Vries, C. Cooper, B. Leufkens, and T.-P. van Staa Reanalysis of two studies with contrasting results on the association between statin use and fracture risk: the General Practice Research Database. Int. J. Epidemiol., October 1, 2006; 35(5): 1301 - 1308. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. L. Lambert, F. E. Cunningham, D. R. Miller, G. W. Dalack, and K. Hur Diabetes Risk Associated with Use of Olanzapine, Quetiapine, and Risperidone in Veterans Health Administration Patients with Schizophrenia Am. J. Epidemiol., October 1, 2006; 164(7): 672 - 681. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Karter, M. M. Parker, H. H. Moffet, M. M. Spence, J. Chan, S. L. Ettner, and J. V. Selby Longitudinal Study of New and Prevalent Use of Self-Monitoring of Blood Glucose Diabetes Care, August 1, 2006; 29(8): 1757 - 1763. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. N. Lemaitre, N. S. Weiss, N. L. Smith, B. M. Psaty, T. Lumley, E. B. Larson, and S. R. Heckbert Esterified estrogen and conjugated equine estrogen and the risk of incident myocardial infarction and stroke. Arch Intern Med, February 27, 2006; 166(4): 399 - 404. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. A. Ray Observational studies of drugs and mortality. N. Engl. J. Med., December 1, 2005; 353(22): 2319 - 2321. [Full Text] [PDF]
|
|
|
|
|
|
P. S. Wang, S. Schneeweiss, J. Avorn, M. A. Fischer, H. Mogun, D. H. Solomon, and M. A. Brookhart Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N. Engl. J. Med., December 1, 2005; 353(22): 2335 - 2341. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E. Scranton, M. Young, E. Lawler, D. Solomon, D. Gagnon, and J. M. Gaziano Statin Use and Fracture Risk: Study of a US Veterans Population Arch Intern Med, September 26, 2005; 165(17): 2007 - 2012. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Prentice, R. Langer, M. L. Stefanick, B. V. Howard, M. Pettinger, G. Anderson, D. Barad, J. D. Curb, J. Kotchen, L. Kuller, et al. Combined Postmenopausal Hormone Therapy and Cardiovascular Disease: Toward Resolving the Discrepancy between Observational Studies and the Women's Health Initiative Clinical Trial Am. J. Epidemiol., September 1, 2005; 162(5): 404 - 414. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hudson, H. Richard, and L. Pilote Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study BMJ, June 11, 2005; 330(7504): 1370. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. P. Johnsen, H. Larsson, R. E. Tarone, J. K. McLaughlin, B. Norgard, S. Friis, and H. T. Sorensen Risk of Hospitalization for Myocardial Infarction Among Users of Rofecoxib, Celecoxib, and Other NSAIDs: A Population-Based Case-Control Study Arch Intern Med, May 9, 2005; 165(9): 978 - 984. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Karter, A. T. Ahmed, J. Liu, H. H. Moffet, M. M. Parker, A. Ferrara, and J. V. Selby Use of Thiazolidinediones and Risk of Heart Failure in People With Type 2 Diabetes: A Retrospective Cohort Study: Response to Delea et al. Diabetes Care, March 1, 2004; 27(3): 850 - 851. [Full Text] [PDF]
|
|